{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-050499","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.628114+00:00","generated_at":"2026-05-29T05:29:21.841548+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC","bullets":["FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.","New dosing aims to reduce medication errors and non-allergic anaphylactoid reactions (NAARs) without compromising efficacy.","Acetadote indicated to prevent/lessen liver injury after acetaminophen overdose, the leading cause of acute liver failure in the US.","Cumberland Pharmaceuticals (CPIX) specialty pharma; CEO A.J. Kazimi highlighted commitment to improving patient care."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-050499","json":"https://secwatch.observer/filing/0001628280-24-050499.json","markdown":"https://secwatch.observer/filing/0001628280-24-050499.md","text":"https://secwatch.observer/filing/0001628280-24-050499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/0001628280-24-050499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024050499/cpix-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:29:21.841548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}